Prevalence and risk assessment of drug allergies in hospitalized patients: Potential for allergy delabeling

IF 4.7 3区医学 Q1 PHARMACOLOGY & PHARMACY

European Journal of Pharmaceutical Sciences Pub Date : 2025-08-21 DOI:10.1016/j.ejps.2025.107240

Robert Nacsa , Maria Matuz , Erika Papfalvi , Helga Hambalek , Roxana Ruzsa , Ni Made Amelia Ratnata Dewi , Edit Hajdu , Fruzsina Reka Ambrus , Zsoka Szikora , Ria Benko

{"title":"Prevalence and risk assessment of drug allergies in hospitalized patients: Potential for allergy delabeling","authors":"Robert Nacsa , Maria Matuz , Erika Papfalvi , Helga Hambalek , Roxana Ruzsa , Ni Made Amelia Ratnata Dewi , Edit Hajdu , Fruzsina Reka Ambrus , Zsoka Szikora , Ria Benko","doi":"10.1016/j.ejps.2025.107240","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Drug allergy prevalence is high and predicted to rise in the future. Although allergy labels are essential for patient safety, evidence supports the fact that incorrectly recorded drug allergy labels might lead to suboptimal treatments, increased healthcare costs, prolonged hospital stays, and the emergence of antimicrobial resistance (AMR). Drug allergy risk assessment and subsequent delabeling could be <strong>a</strong> solution for this problem. Despite the importance of this subject, the number of studies on the prevalence of drug allergies or delabeling is low, especially from Eastern European countries.</div></div><div><h3>Aims</h3><div>This study aimed to determine the prevalence and characteristics of drug allergies in hospitalized patients and assess the associated risk of future exposure to the reported culprit drugs to evaluate the potential for allergy delabeling.</div></div><div><h3>Methods</h3><div>A cross-sectional study was conducted at the tertiary care teaching hospital of University of Szeged in Hungary, involving adult inpatients across multiple surgical wards. Data collection included patient interviews using a structured questionnaire and subsequent risk assessment. Adverse drug reactions were categorized as high or low risk based on the history of the reported reaction.</div></div><div><h3>Results</h3><div>Of the 1522 study participants, 242 (15.90 %, 95 % CI: 14.14 - 17.82 %) patients reported at least one drug allergy, resulting in a total of 384 reported allergy cases. Among these, 277 cases were included in the risk assessment, with 252 (90.97 %) classified as low risk and eligible for potential allergy delabeling. Antibiotics were the most frequently reported culprit drug, followed by analgesics and anti-inflammatory drugs. Skin manifestations were the most common symptoms.</div></div><div><h3>Conclusion</h3><div>This study highlights the high prevalence of self-reported drug allergies and the significant proportion of low-risk cases suitable for delabeling. Systematic allergy evaluation and delabeling should be a key element of (antibiotic) stewardship programs.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"213 ","pages":"Article 107240"},"PeriodicalIF":4.7000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0928098725002398","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Drug allergy prevalence is high and predicted to rise in the future. Although allergy labels are essential for patient safety, evidence supports the fact that incorrectly recorded drug allergy labels might lead to suboptimal treatments, increased healthcare costs, prolonged hospital stays, and the emergence of antimicrobial resistance (AMR). Drug allergy risk assessment and subsequent delabeling could be a solution for this problem. Despite the importance of this subject, the number of studies on the prevalence of drug allergies or delabeling is low, especially from Eastern European countries.

Aims

This study aimed to determine the prevalence and characteristics of drug allergies in hospitalized patients and assess the associated risk of future exposure to the reported culprit drugs to evaluate the potential for allergy delabeling.

Methods

A cross-sectional study was conducted at the tertiary care teaching hospital of University of Szeged in Hungary, involving adult inpatients across multiple surgical wards. Data collection included patient interviews using a structured questionnaire and subsequent risk assessment. Adverse drug reactions were categorized as high or low risk based on the history of the reported reaction.

Results

Of the 1522 study participants, 242 (15.90 %, 95 % CI: 14.14 - 17.82 %) patients reported at least one drug allergy, resulting in a total of 384 reported allergy cases. Among these, 277 cases were included in the risk assessment, with 252 (90.97 %) classified as low risk and eligible for potential allergy delabeling. Antibiotics were the most frequently reported culprit drug, followed by analgesics and anti-inflammatory drugs. Skin manifestations were the most common symptoms.

Conclusion

This study highlights the high prevalence of self-reported drug allergies and the significant proportion of low-risk cases suitable for delabeling. Systematic allergy evaluation and delabeling should be a key element of (antibiotic) stewardship programs.

Abstract Image

查看原文本刊更多论文

住院患者药物过敏的患病率和风险评估：潜在的过敏去除标签

药物过敏的患病率很高，预计未来还会上升。尽管过敏标签对患者安全至关重要，但有证据表明，记录不正确的药物过敏标签可能导致不理想的治疗，增加医疗费用，延长住院时间，并出现抗微生物药物耐药性（AMR）。药物过敏风险评估和随后的去标签可能是解决这个问题的办法。尽管这一主题很重要，但关于药物过敏或去标签的患病率的研究数量很少，特别是来自东欧国家的研究。目的本研究旨在确定住院患者药物过敏的患病率和特征，并评估未来暴露于报告的罪魁祸首药物的相关风险，以评估过敏标签去除的可能性。方法在匈牙利塞格德大学三级保健教学医院进行横断面研究，涉及多个外科病房的成年住院患者。数据收集包括使用结构化问卷的患者访谈和随后的风险评估。根据报告的不良反应史，将药物不良反应分为高风险和低风险。结果在1522名研究参与者中，242名（15.90%,95% CI: 14.14 - 17.82%）患者报告至少有一种药物过敏，总共384例报告过敏病例。其中纳入风险评估的277例，其中252例（90.97%）为低风险，符合潜在过敏去除标签的条件。抗生素是最常见的罪魁祸首，其次是镇痛药和消炎药。皮肤表现是最常见的症状。结论本研究强调了自我报告的药物过敏发生率高，适合去标签治疗的低风险病例占很大比例。系统的过敏评估和去标签应该是（抗生素）管理计划的关键要素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Pharmaceutical Sciences 医学-药学

CiteScore

9.60

自引率

2.20%

发文量

248

审稿时长

50 days

期刊介绍： The journal publishes research articles, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and development. More specifically, the Journal publishes reports on medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery (including gene delivery), drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. The journal will typically not give priority to manuscripts focusing primarily on organic synthesis, natural products, adaptation of analytical approaches, or discussions pertaining to drug policy making. Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal.